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Background: There is a lack information on the effects of the most commonly used anticoagulants for equine
platelet rich plasmas (PRPs) elaboration on cell counts and growth factor release from platelet rich gels (PRGs). The
aims of this study were 1) to compare the effects of the anticoagulants sodium citrate (SC), acid citrate dextrose
solution A (ACD-A) and ACD-B on platelet (PLT), leukocyte (WBC) and on some parameters associated to platelet
activation including mean platelet volume (MPV) and platelet distribution width (PDW) between whole blood, pure
PRP (P-PRP) and platelet-poor plasma (PPP); 2) to compare transforming growth factor beta 1 (TGF-β1) and
platelet-derived growth factor isoform BB (PDGF-BB) concentrations in supernatants from pure PRG (P-PRG),
platelet-poor gel (PPG), P-PRP lysate (positive control) and plasma (negative control); 3) to establish the possible
correlations between all the studied cellular and molecular parameters.
Results: In all cases the three anticoagulants produced P-PRPs with significantly higher PLT counts compared
with whole blood and PPP. The concentrations of WBCs were similar between P-PRP and whole blood, but
significantly lower in PPP. The type of anticoagulant did not significantly affect the cell counts for each blood
component. The anticoagulants also did not affect the MPV and PDW parameters. Independently of the anticoagulant
used, all blood components presented significantly different concentrations of PDGF-BB and TGF-β1. The highest
growth factor (GF) concentrations were observed from P-PRP lysates, followed by PRG supernatants, PPP lysates, PPG
supernatants and plasma. Significant correlations were observed between PLT and WBC counts (ρ = 0.80), PLT count
and TGF-β1 concentration (ρ = 0.85), PLT count and PDGF-BB concentration (ρ = 0.80) and PDGF-BB and TGF-β1
concentrations (ρ = 0.75). The type of anticoagulant was not correlated with any of the variables evaluated.
Conclusions: The anticoagulants did not significantly influence cell counts or GF concentrations in equine PRP.
However, ACD-B was apparently the worst anticoagulant evaluated. It is necessary to perform additional research
to determine the effect of anticoagulants on the kinetics of GF elution from P-PRG.
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There is an increased use of platelet-rich plasma (PRP)
as a treatment for musculoskeletal diseases and severe
wounds in horses [1-4]. It was recognized that among
the regenerative therapies, platelet-rich plasma (PRP) is
an autologous platelet concentrate suspended in plasma
that, administrated in the wound site, releases growth
factors and promotes the wound healing cascade [2,5].
Platelets contain a pool of growth factors, including
transforming growth factor-b (TGF-β), platelet derived
growth factor (PDGF) and vascular endothelial growth
factor (VEGF), mainly contained in platelet alpha gran-
ules [6] that are released after platelet degranulation in
the damage site and enhance tissue regeneration by
stimulating cell proliferation, increasing extracellular
matrix synthesis, promoting vascular ingrowth and redu-
cing catabolic matrix-degrading cytokines such as inter-
leukins and matrix metalloproteinases [5,7].
PRP intended for regenerative proposes may be classi-
fied as: pure-platelet rich plasma (P-PRP) or leukore-
duced PRP, leukocyte- and platelet-rich plasma (L-PRP)
and platelet rich fibrin (PRF). P-PRP and L-PRP are ob-
tained in a liquid form by using anticoagulants [8]. PRF
is a second generation platelet concentrate, which does
not require anticoagulant for its elaboration. In horses,
P-PRP displays slightly higher platelet counts (1.3 - 4.0
fold) and leukocyte (WBC) counts (0.5 - 2.0 fold) than
whole blood, whereas L-PRP has increased platelet
(5 fold) and leukocyte (3 - fold or more) counts when
compared with whole blood. There is not a complete
consensus regarding the role of leukocyte concentrations
in PRP [2]. However, in vitro evidence suggests that
leukoreduced PRP could be more suitable for the
treatment of tendon and soft tissue injuries in horses, as
this substance induces tendon anabolism and decreases
the expression of catabolic cytokines when compared
with L-PRP [9].
Although PRP (either L-PRP or P-PRP) is employed as
a promising treatment in equine practice [5], there are
some controversial issues that should solved to improve
the clinical use of this substance in horses and other ani-
mals. There are a plethora of PRP products and PRP-
associated technologies that are used in human and
equine practices [2,8,10]. However, little is known
regarding the cellular and molecular quality of these
substances, as they are influenced by intrinsic factors
that are dependent on the patient, such as gender, age,
breed [6] and pathological conditions [11], amongst
others and by extrinsic factors, such as the type of anti-
coagulant used [12], the relative centrifugation forces
(rcf or g) used for cell concentration [2,13,14], the type
and form of the kit used for PRP preparation and the ac-
tivating substance used for PRP activation and growth
factor release [2,15].Recent equine PRP studies have showed that the cell
and growth factor release profiles are influenced by the
intrinsic factors of the patients [6]. Furthermore, it has
also been observed that activating substances, including
calcium salts and thrombin, affect the growth factor re-
lease profile from equine PRP [15]. However, there is a
lack of information of the effect on the most commonly
used anticoagulants for PRP elaboration on cell counts
and growth factor release. Although, a human study in-
dicated that acid citrate dextrose solution A (ACD-A)
was better than sodium citrate (SC) for PRP prepar-
ation [12], there is no information regarding the effect
of the type of anticoagulant used for PRP preparation
in horses on cell counts from PRP or growth factor re-
lease from PRG.
The aims of this study were: 1) to compare the effects
of the anticoagulants SC, ACD-A and ACD-B on platelet
and leukocyte counts and platelet activation associated
parameters, such as mean platelet volume (MPV) and
platelet distribution width (PDW) between whole blood,
P-PRP and platelet-poor plasma (PPP); 2) to compare
the PDGF-BB and TGF-β1 concentrations in the super-
natants from pure platelet-rich gel (P-PRG), platelet-
poor gel (PPG), P-PRP lysate (positive control) and
plasma (negative control); 3) to establish the possible
correlations between all the studied cellular and molecu-
lar parameters.
The hypothesis of this study was that anticoagulants
do not influence cell counts and PDGF-BB and TGF-β1
release from equine P-PRP/P-PRG.
Methods
This study was approved by the Ethical Committee of
the Universidad de Caldas.
Horses
Eighteen clinically normal Argentinean Creole horses
(geldings) were used. The horses had a mean age of 12.5
(± standard deviation (s.d) 6.3) years old. All the horses
were from the same farm, and the owner did know the
nature of the study and authorized the blood extraction
accordingly.
Blood collection and preparation of platelet concentrates
From each animal blood samples were collected in tripli-
cate by jugular venipuncture and deposited randomly in
tubes with either sodium citrate (SC) (12.35 mg sodium
citrate and 2.21 mg citric acid [BD Vacutainer®, Becton
Drive, Franklin Lakes, NJ, USA]) or acid citrate dextrose
(ACD) solution A (ACD-A) (22.0 g/L trisodium citrate,
8.0 g/L citric acid and 24.5 g/L dextrose [BD Vacutainer®,
Becton Drive, Franklin Lakes, NJ, USA]) or ACD solution
B (ACD-B) (13.2 g/L trisodium citrate 4.8 g/L citric acid
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Tubes with each anticoagulant were randomly proc-
essed for P-PRP production. The total whole blood
used for P-PRP preparation using each anticoagulant
varied between 110 and 140 mL. Briefly, after centrifu-
gation at 120 g for 5 min, the first 50% of the top
supernatant plasma fraction, adjacent to the buffy coat,
was collected. This fraction was then centrifuged at
240 g for 5 min and the bottom quarter fraction was
collected [16]. This fraction was considered to be P-
PRP. The upper plasma fraction P-PRP was considered
to be PPP (Figure 1). Plasma was obtained by centrifu-
gation from each anticoagulated blood at 3500 g for
8 min. The time between blood collection and process-
ing was approximately 1 h. All the samples were
deposited and transported from the farm to the labora-
tory in an icebox.Haematological analysis
Complete, automated haemograms (Celltac-α MEK
6450, Nihon Kodhen, Japan) were performed in dupli-
cate for whole blood, P-PRPs and PPPs obtained from
each anticoagulant. Platelet (PLT) counts, mean platelet
volume (MPV fL), platelet distribution width (PDW %)
and total leukocyte (WBC) counts were determined.Figure 1 Schematic representation of the plasma fractions obtained w
fraction of plasma (50%) (PFP) obtained by the single centrifugation tube m
by the double centrifugation tube method. BC: buffy coat. PCV: packed celActivation of platelet concentrates
Four hundred μL of a 10% calcium gluconate (CG) solu-
tion (9.3 mg/mL) (Ropsohn Therapeutics Ltda®, Bogotá,
Colombia) was added to 4 mL of P-PRP or PPP obtained
with each anticoagulant to produce the P-PRGs and
PPGs, respectively. P-PRGs and PPGs were incubated at
37°C for 3 h to stimulate GF release. Clots were mech-
anically released from the walls of the tubes and centri-
fuged at 3500 g for 8 min. The resulting supernatant was
aliquoted, and frozen at −82°C for later determination of
TGF-β1 and PDGF-BB concentrations.
Lysis of platelet concentrates
Samples of 4 mL of P-PRPs and PPPs obtained using each
anticoagulant were incubated at 37°C for 15 min with
400 μL of a solution containing 0.5% of a non-ionic deter-
gent (NID) (Triton® X100, Panreac Química, Barcelona,
Spain). Platelet concentrates treated with NID were used
as a positive control for GF release [11]. Lysates were
processed in a similar fashion to supernatants from P-
PRGs and PPGs.
Total protein determination
Total protein (TP) concentration from all the samples
were determined using the biuret method (Proteína total
(Biuret), BioSystems, Barcelona, Spain) [17], followed by
spectrophotometric quantifications.ith the tube method protocol. Left tube (A) containing the first
ethod. Right tube (B) containing platelet-rich plasma (PRP) obtained
l volume.
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ELISA
The TGF-β1 and PDGF-BB concentrations from the
supernatants and lysates of each blood component were
determined in duplicate by a sandwich ELISA using
commercially available antibodies against human TGF-
β1 (Human TGF-β1, DY240E, R&D Systems, Inc.,
Minneapolis, MN USA) and PDGF-BB (Human PDGF-
BB, DY220, R&D Systems, Inc.). Both ELISAs were per-
formed according to the manufacturer’s instructions.
Readings were performed at 450 nm. Both ELISAs were
determined with human antibodies because there is a
high homology of these growth factors between equines
and humans [18,19]. Further, several equine PRP studies
have validated these ELISA kits [6,14-16].
Statistical analysis
Data were analysed using commercial software (SPSS 18.0,
IBM, Chicago, IL, USA). Data were initially assessed for
normality (goodness of fit) by a Shapiro-Wilk test and a
direct plot analysis of each evaluated variable. When the
variables had a normal distribution (Shapiro-Wilk test,
P > 0.05), they were presented as means (± s.d.) and
evaluated by parametric tests (e.g., Student’s t-test for
paired samples, and one way analysis of variance
(ANOVA) and Tukey’s test (for post-hoc paired com-
parisons). Non-parametric variables (Shapiro-Wilk
test, P <0.05) were presented as medians (interquartile
range -IR-) and evaluated using a Kruskal-Wallis test
followed, when necessary, by a Mann–Whitney U-test.
A Wilcoxon test was used for non-related paired com-
parisons. All the variables were analysed for general and
specific correlations using a Spearman (rs) test. A P value
≤0.05 was considered to be significant for all tests.
Results
Haematological findings
In all cases, the three anticoagulants produced P-PRPs
with significantly (P < 0.001) higher PLT counts com-
pared with whole blood and PPP. The concentrations of
WBCs were similar between P-PRP and whole blood,Table 1 Means (± s.d) of the haematological variables for eac
Variable Anticoagulant
Sodium citrate (SC) ACD-A
Whole blood P-PRP PPP Whole blood
PLT (103/μL) 143.8 (19.4)a,b 390.6 (57.6)c 111.0 (22.6) 137.0 (21.3)a
MPV (fL) 3.8 (0.4) 4.1 (0.6)b 3.6 (0.3) 3.8 (0.4)
PDW (%) 16.5 (0.5)c 16.8 (0.5)c 17.8 (0.5) 16.3 (0.5)c
WBC (103/μL)* 8.4 (1.7)c,d 9.5 (3.0)c 0.1 (0.0) 7.9 (2.0)c,d
ACD: acid citrate dextrose (solution-A,-B); P-PRP: pure platelet-rich plasma; PPP: plat
distribution width; WBC: white blood cells. Lower-case letters represent significant d
Blood components significantly different with a: P-PRP (P <0.001); b: PPP (P <0.05);
presented as medians (interquartile range (IR).but significantly (P < 0.001) lower in PPP. The type of
anticoagulant did not significantly affect the cell counts
for each blood component. The anticoagulants also did
not affect the MPV and PDW parameters. However, in
general, these platelet activation parameters were signifi-
cantly higher in P-PRP than in PPP. A summary of the
haematological results is shown in Table 1.
Growth factor release from blood components
Independently of the anticoagulant used, all blood compo-
nents presented significantly different concentrations of
PDGF-BB and TGF-β1. The highest GF concentrations
were observed from P-PRP lysates, followed by PRG su-
pernatants, PPP lysates, PPG supernatants and plasma
(Table 2). However, when data were plotted, a statistical
trend (P = 0.20) was observed for PDGF-BB concentra-
tions in P-PRG from SC in comparison with ACD-B
(Figure 2). In contrast, this trend was not observed for
TGF-β1 released from P-PRG (Figure 3).
Correlations
Significant correlations were observed between PLT and
WBC counts (ρ = 0.80, P <0.01), PLT counts and TGF-β1
concentrations (ρ = 0.85, P <0.01), PLT counts and
PDGF-BB concentrations (ρ = 0.80, P <0.01) and PDGF-
BB and TGF-β1 concentrations (ρ = 0.75, P <0.01). The
type of anticoagulant was not correlated with any of the
variables evaluated.
Discussion
To our knowledge, this is the first study to evaluate the
effects of several anticoagulants used for producing
equine PRP as a regenerative therapy. The cellular re-
sults from this study were similar to those previously re-
ported by other equine PRP studies, in which the double
centrifugation tube method was used [6,13].
The parameters associated with platelet activation,
such as MPV and PDW were not affected by the type of
anticoagulant evaluated in this study. However, MPV
and PDW values were significantly lower in PPP when
compared with whole blood and P-PRP, although theyh blood component obtained with every anticoagulant
ACD-B
P-PRP PPP Whole blood P-PRP PPP
399.1 (62.8)c 112.6 (23.7) 137.1 (25.4)a 398.5 (48.0)c 111.2 (18.5)
4.2 (0.6)b 3.7 (0.4) 3.8 (0.4)d 4.2 (0.5)b 3.7 (0.4)
16.5 (0.6)c 17.6 (0.7) 16.1 (0.6)c 16.7 (0.6)c 17.8 (0.7)
9.8 (5.0)c 0.1 (0.0) 8.3 (2.3)e 10.6 (4.0)c 0.1 (0.0)
elet-poor plasma; PLT, platelets; MPV: mean platelet volume; PDW: platelet
ifferences between blood components for every independent anticoagulant.
c: PPP (P <0.001); d: P-PRP (P <0.05); and e: P-PRP PPP (P <0.001); *Data are
Table 2 Means (± s.d) of the TGF-β1and PDGF-BB concentrations (pg/mg of total protein (TP)) in every blood component
obtained with every anticoagulant
Variable Blood component
Plasma P-PRP lysate P-PRG PPP lysate PPG
SC
PDGF-BB (pg/mg of TP) 0.9 (0.6)a,b 25.2 (14.4)c 19.0 (29.4)d 8.3 (5.4)d 4.5 (5.5)
TGF-β1(pg/mg of TP)* 26.8 (10.4)a,e 90.7 (30.7)c,e 54.5 (33.1) 45.2 (10.3)d 29.2 (17.1)
ACD-A
PDGF-BB (pg/mg of PT) 1.0 (0.6)a,b 28.2 (20.1)c 11.3 (30.6) 8.2 (5.0) 5.8 (8.0)
TGF-β1(pg/mg of TP)* 30.0 (8.7)a 101.5 (31.2)c,e 56.4 (39.1) 47.8 (12.2) 33.3 (17.9)
ACD-B
PDGF-BB (pg/mg of TP) 1.1 (0.9)a 18.4 (13.4)b 6.6 (17.3) 7.2 (4.1) 4.8 (6.5)
TGF-β1(pg/mg of TP)* 27.5 (10.0)c 87.8 (23.0)d 50.8 (31.2) 44.6 (12.9) 31.3 (12.7)
*Data are presented as medians (IR). P-PRG: pure platelet-rich gel; PPG: platelet-poor gel. Lowercase letters represent independent significant differences for every
blood component obtained with a specific anticoagulant. SC: blood component different with a: P-PRP and PPP lysates (P <0.001); b: P-PRG and PPG (P <0.05); c:
PPP lysate and PPG (P <0.001); d: PPG (P <0.05); and e: P-PRG (P <0.05). ACD-A: blood component different with a: P-PRP and PPP lysates (P <0.001); b: P-PRG and
PPG (P <0.05); c: PPP lysate and PPG (P <0.001); d: PPG; and e: P-PRG (P <0.05). ACD-B: blood component different a: all blood components (P <0.05); b: PPP lysate
and PPP (P <0.05); c: P-PRP lysate (P <0.05); d: PPP lysate and PPG (P <0.05).
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species [6]. It is known, that ACD is a very good anti-
coagulant, compared to SC for preserving the structural
and physiological properties of platelets after two or
more hours of blood collection [20]. From a regenerative
medicine perspective, ACD should be used to conserve
PLT integrity in situations in which the processing (and
transporting) of the blood samples could take two or
more hours before the PRP can be used.Figure 2 Means (standard error of the mean (s.e.m)) of PDGF-BB conc
letters denote significant differences between blood components for every
significantly different with a: pure platelet-rich plasma (P-PRP) lysate and pl
(P-PRG) and platelet poor gel (PPG) (P <0.05); c: PPG and PPP lysate (P <0.0
blood component significantly different with a: P-PRP lysate, PPP lysate, P-PRG
(P <0.05). ACD-B: blood component significantly different with a: P-PRP and P
lysates (P <0.001).Although the type of anticoagulant did not signifi-
cantly influence the PDGF-BB and TGF-β1 concentra-
tions in the different blood components in the present
study, there was a better apparent concentration of
PDGF-BB in the blood components processed with SC,
followed by ACD-A and ACD-B. In contrast, when
TGF-β1 concentrations were evaluated, there were better
apparent concentrations of this GF in the blood compo-
nents processed with ACD-A, followed by SC and ACD-entration (pg/mL) in the different blood components. Lower-case
independent anticoagulant. Sodium citrate (SC): blood component
atelet poor plasma (PPP) lysate (P <0.001); b: pure platelet-rich gel
01); and d: PPG (P <0.05). Acid citrate dextrose solution A (ACD-A):
and PPG (P <0.001); b: PPG and PPP lysates (P <0.001); and c: P-PRG
PP lysates (P <0.001); b: P-PRG and PPG (P <0.05); and c: PPG and PPP
Figure 3 Means (s.e.m) of TGF-β1concentration (pg/mL) in the different blood components. Lower-case letters denote significant differences
between blood components for every independent anticoagulant. SC: blood component significantly different with a: P-PRP lysate (P <0.001); b: P-PRG
and PPP lysates (P <0.05); c: PPG and PPP lysates (P <0.001); d: P-PRG (P <0.05); and e: PPG (P <0.05). ACD-A: blood component significantly different
with a: P-PRP and PPP lysates (P <0.001); b: PPG and PPP lysates (P <0.001); c: P-PRG (P <0.05); and d: PPG (P <0.05). ACD-B: blood component significantly
different with a: PRP and PPP lysates (P <0.001); b: P-PRG (P <0.05); c: PPG and PPP lysates (P <0.001); d: P-PRG (P <0.001); and e: PPG (P <0.05).
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tained with ACD-A and SC [12].
Notably, ACD-B had a very negative influence on GF
concentrations when compared with the other anticoag-
ulants. It is possible that the type of anticoagulant influ-
enced (albeit not significantly) the release patterns of
both GFs from all P-PRGs, as PDGF-BB release was sub-
stantially larger from platelet clots processed with SC in
comparison with ACD-A and ACD-B. In contrast, TGF-
β1 release was more uniform (50% of the concentration
with respect to P-PRP lysates) from the P-PRGs obtained
with any of the three anticoagulants.
Despite the intriguing results observed regarding GF
release from P-PRGs, the present study may have had
some methodological limitations. For instance, perhaps
measuring GF release at a single time point is not appro-
priate for determining the exact influence of the antico-
agulants on GF release from P-PRGs [15]. In this
situation, it is imperative to perform a study that evalu-
ates the elution kinetics of both GFs at several time
points. This study is necessary to determine whether the
type of anticoagulant could produce GF loss (degrad-
ation) or GF absorption in the P-PRGs.
Many P-PRPs produced by manual tube protocols in
different species (including equines) are performed with
commercial vacuum tubes for in vitro diagnoses, not for
therapeutic purposes [6,13,21,22]. This is a well-
manifested concern by researches defending the use of
commercial kits for producing platelet concentrates [23].
However, in the experience of the authors, the only prob-
lem with using commercial tubes with anticoagulants forequine PRP processing is that the PLT collection efficiency
is very low [6,16]. The use of many tubes during PRP
preparation could be associated with a risk of bacterial
contamination [24] and with a major time expenditure for
PRP processing [2]. However, it is well recognized that the
main source for bacterial contamination during PRP pro-
cessing is the skin of the venipuncture site, not the tubes
[24]. In view of these limitations, it is possible that the use
of ACD-A tubes could be more suitable for manual PRP
processing, as the volume capacity of the tubes is almost
44% greater than that of sodium citrate tubes.
The correlations obtained in this study were similar to
those obtained in previous equine PRP studies, which
evaluated manual protocols [6,16]. In general, there were
moderate to strong correlations between cell (PLT and
WBC) counts and GF concentrations. These findings are
in agreement with several procedures for obtaining PRP
in humans [25], dogs [26] and cattle [27]. The role of
WBCs in PRP is controversial because there are data
supporting the catabolic effect of these cells in equine
tendon explants [9]. However, this situation could be
more clinically relevant when L-PRP preparations are
used [28]. The authors believe that the number of WBCs
concentrated in the P-PRPs from this study could be
beneficial for treating tissues because these cells are cor-
related with GF concentrations, especially TGF-β1 [6].
Conclusions
This study presents new information regarding the effect
of the anticoagulants: SC, ACD-A and ACD-B, for the
elaboration of equine P-PRP. The results obtained in the
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ulants evaluated did not significantly influence cell
counts or GF concentrations in equine P-PRP. However,
ACD-B was apparently the worst anticoagulant evalu-
ated, because it produced the lower cell counts and GF
concentrations when compared with the other two anti-
coagulants. It is necessary to perform additional research
to determine the GF elution kinetics from P-PRGs
obtained with the anticoagulants evaluated in this study.
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